TG Therapeutics Reports Positive Phase 1 Data for BRIUMVI in Myasthenia Gravis, Initiates Phase 2 Trial — TG Therapeutics, Inc.

Event summary

TG Therapeutics reported positive topline Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis (MG) patients, with 82% achieving a Minimal Clinically Important Difference (MCID) in MG-ADL.
The Phase 1 study involved 11 patients with AChR-antibody-positive MG, showing a mean 4.6-point improvement in MG-ADL at Week 24.
TG Therapeutics initiated a potentially registration-directed Phase 2 trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod.
The Phase 2 trial will enroll approximately 120 patients and assess the efficacy and safety of BRIUMVI in maintaining clinical response in MG patients.

The big picture

TG Therapeutics' positive Phase 1 data for BRIUMVI in MG and the initiation of a Phase 2 trial represent a strategic pivot into a new therapeutic area, leveraging the drug's proven efficacy in multiple sclerosis. The novel sequential treatment approach aims to address the unmet need for durable disease control in MG, potentially reducing the treatment burden associated with chronic FcRn therapy. This move aligns with broader industry trends towards targeted therapies for autoimmune diseases, highlighting the company's focus on expanding its commercial portfolio.

What we're watching

Clinical Efficacy: Whether the sequential treatment approach combining FcRn inhibition with B-cell depletion will establish a differentiated treatment paradigm in MG.
Regulatory Pathway: The pace at which the Phase 2 trial data will support a potential registration submission for BRIUMVI in MG.
Market Expansion: How the expansion of BRIUMVI's utility beyond multiple sclerosis into MG will impact TG Therapeutics' commercial strategy.